Search Results - vaccines

39 Results

Sort By:

Combination Cancer Therapy Methods and Agents (UCLA Case No. 2024-084)

UCLA researchers from the Department of Medicine, Pathology, & Laboratory Medicine and Molecular & Medical Pharmacology have identified a novel cell-based therapy that leads to enhanced immunotherapy efficacy and overcomes treatment resistance to immune checkpoint blockade in non-small cell lung cancer. BACKGROUND: Non-small cell lung cancer...

Published: 11/4/2024 | Inventor(s): Bin Liu, Steven Dubinett

Keywords(s): anti-tumor immunity, cell-based therapy, Immune checkpoint blockade, Immunotherapy, non-small cell lung cancer, treatment resistance, Tumor microenvironment, Vaccines

Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy, Therapeutics > Respiratory And Pulmonary

Raman Spectroscopy for Testing Stability of RNA-based Vaccines and Drugs

A fast, less expensive, and more reliable method for assessing mRNA degradation in vaccines, that can also be used as a tool for the development of new RNA-based therapeutics. Background: The development of mRNA-based vaccines for COVID-19 offers the potential for a new medical paradigm based on RNA technology. Unfortunately, these drugs require...

Published: 12/10/2024 | Inventor(s): Igor Lednev, Alexander Shekhtman, Lamyaa Almehmadi, Sergei Reverdatto

Keywords(s): drug stability, mRNA, mRNA stability, Raman spectroscopy, RNA, Technologies, vaccine stability, vaccines

Category(s): Campus > University at Albany, Technology Classifications > Biomedical Science and Engineering, Technology Classifications > Therapeutics and Vaccines, Technology Classifications > Viral Vectors

A Vaccine Technology for Preventing Clostridioides difficile Infection Using Cell Wall Protein 2 (CWP 2)

Advantages: A recombinant Cwp2 protein that induces strong IgG and IgA antibody response in animal models. Decrease levels of C. difficile spores and toxins in feces and decrease mortality rates in immunized mice. Anti-Cwp2 antibodies delay the binding of C. difficile vegetative cells to human gut epithelial cells and prevent bacterial colonization....

Published: 9/17/2024 | Inventor(s): Xingmin Sun, Shaohui Wang

Keywords(s): Vaccines

Category(s): Technology Classifications > Medical > Pharmaceuticals, Technology Classifications > Medical, Technology Classifications > Medical > Biotechnology

Kaposi Sarcoma Associated Herpesvirus Vaccine Development (UCLA Case No. 2023-038)

UCLA researchers in the Department of Molecular and Medical Pharmacology have a novel discovery showing the potential benefit of engaging complement-mediated antibody functions in future KSHV vaccine development. BACKGROUND: Kaposi Sarcoma Associated Herpesvirus (KHSV) is the etiological agent for cancers such as Kaposi Sarcoma (KS) and primary...

Published: 4/16/2024 | Inventor(s): Ting-Ting Wu

Keywords(s): herpes, herpesvirus, kaposi sarcoma, Vaccines

Category(s): Therapeutics > Vaccines

Summary: UCLA researchers have developed a software to accelerate vaccine clinical trial processes by modeling disease behavior and targeting future trial participants. Background: Vaccine clinical trials are time-intensive processes; ones that may be necessary during active pandemics in which time is of short supply. One of the primary factors contributing...

Published: 11/15/2024 | Inventor(s): Akihiro Nishi

Keywords(s): Bioinformatics, Clinical Trial, Live attenuated vaccine, Public Health, Simulation & Modeling, Software & Algorithms, Therapeutics & Vaccines, Vaccines

Category(s): Software & Algorithms > Statistical Models, Software & Algorithms > Bioinformatics

Biomaterial-Based Vaccine Booster to Enhance Long-Term Immunity (UCLA Case No. 2021-170)

UCLA researchers have developed injectable, cell-free, and biomaterial-based microparticles that can engage with tissue resident immune cells and enhance long-term immunity. It is the first biomaterial-based, targeted approach to induce T memory stem cells (TMSCs) in vivo. The approach was demonstrated for SARS-CoV-2 but can be used for any vaccine....

Published: 2/26/2024 | Inventor(s): Mohammad Hasani-Sadrabadi, Song Li, Manish Butte

Keywords(s): aAPCs, Aging, artificial presenting cells, cytokines, elderly, immunosenescence, microparticles, platform technology, SARS-CoV-2, T memory stem cells, TMSCs, Vaccines

Category(s): Therapeutics > Infectious Diseases, Therapeutics > Oncology

Novel Safe Potent Single Vector Platform Vaccines Against Melioidosis (UCLA Case No. 2023-119)

UCLA researchers in the School of Medicine have developed a novel single-vector platform vaccine for preventing melioidosis, an infection caused by Burkholderia pseudomallei. BACKGROUND: Melioidosis, also known as Whitmore’s disease, is an infectious disease that can infect both humans and animals. The bacterium Burkholderia pseudomallei (Bp)...

Published: 2/21/2024 | Inventor(s): Marcus Horwitz

Keywords(s): Burkholderia pseudomallei, Intracellular Pathogens, Live attenuated vaccine, Melioidosis, Pathogen, Select Agents, Tier 1 Diseases, Vaccines

Category(s): Therapeutics > Infectious Diseases

Receptor Binding Domain 2 of CDTb Component of the Clostridioides Difficile Binary Toxin CDT as a Vaccine Component Against C. Difficile Infection

Advantages: Enhanced Vaccine Conservation: This technology ensures the conservation of critical vaccine components across diverse C. difficile strains, improving vaccine effectiveness. Immunogenic Potential: RBD2, a key discovery, exhibits exceptional immunogenicity, promising robust immune responses in vaccine recipients. Inhibition of CDT...

Published: 9/3/2024 | Inventor(s): Xingmin Sun, Shaohui Wang

Keywords(s): Infectious Diseases, Vaccines

Category(s): Technology Classifications > Medical > Infectious Diseases

Recombinant Fusion Protein Containing Clostridioides Difficile Flagellin Proteins FliC and FliD as a Vaccine Candidate Against C. Difficile Infection

Advantages: Novel Vaccine Approach: Vacine targeting C. difficile flagellar proteins FliC and FliD. Enhanced Protection: FliCD provides robust immunity, reduces C. difficile infection severity, and decreases spore and toxin levels in feces. Potential Alternative Therapy: Anti-FliCD serum demonstrates promise as an adjunct therapy for CDI,...

Published: 2/13/2024 | Inventor(s): Xingmin Sun

Keywords(s): Infectious Diseases, Vaccines

Category(s): Technology Classifications > Medical > Infectious Diseases

A Dendritic Cell Vaccine to Immunize Cancer Patients Against Mutated Neoantigens Expressed by the Autologous Cancer

Abstract: Vaccines against non-viral cancers target mainly differentiation antigens, cancer testis antigens, and overexpressed antigens. One common feature to these antigens is their presence in central immunological tolerance. Using these vaccines, T cells underwent depletion of high avidity clones directed against such antigens. This depletion can...

Published: 4/8/2024 | Inventor(s): Gal Cafri, Paul Robbins, Jared Gartner, Steven Rosenberg

Keywords(s): CANCER, Dendritic cells, Immunotherapy, Neoantigens, Rosenberg, T Cells, vaccines

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Vaccines

1 2 3 4